Terms: = Breast cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Clinical Outcome
16 results:
1. Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial.
Cao J; Teng Y; Li H; Zhang L; Ouyang Q; Xie W; Pan Y; Song Z; Ling X; Wu X; Xu J; Li L; Ren L; Wang H; Zhou D; Luo J; Hu X
BMC Med; 2023 Aug; 21(1):300. PubMed ID: 37559142
[TBL] [Abstract] [Full Text] [Related]
2. Lymphoproliferative disease detected by breast cancer screening.
Luttwak E; Segman Y; Saban M; Gutwein O; Avivi I; Perry C; Filiavich A; Sarid N
J Med Screen; 2022 Dec; 29(4):255-259. PubMed ID: 35818749
[TBL] [Abstract] [Full Text] [Related]
3. Development and validation of an individualized nomogram for predicting the high-volume (> 5) central lymph node metastasis in papillary thyroid microcarcinoma.
Wei X; Min Y; Feng Y; He D; Zeng X; Huang Y; Fan S; Chen H; Chen J; Xiang K; Luo H; Yin G; Hu D
J Endocrinol Invest; 2022 Mar; 45(3):507-515. PubMed ID: 34491546
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic Significance of Patient-Reported outcomes in cancer.
Kerrigan K; Patel SB; Haaland B; Ose D; Weinberg Chalmers A; Haydell T; Meropol NJ; Akerley W
JCO Oncol Pract; 2020 Apr; 16(4):e313-e323. PubMed ID: 32048943
[TBL] [Abstract] [Full Text] [Related]
5. High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
Hollis RL; Churchman M; Michie CO; Rye T; Knight L; McCavigan A; Perren T; Williams ARW; McCluggage WG; Kaplan RS; Jayson GC; Oza A; Harkin DP; Herrington CS; Kennedy R; Gourley C
Cancer; 2019 Aug; 125(16):2772-2781. PubMed ID: 31154673
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline
Somlo G; Frankel PH; Arun BK; Ma CX; Garcia AA; Cigler T; Cream LV; Harvey HA; Sparano JA; Nanda R; Chew HK; Moynihan TJ; Vahdat LT; Goetz MP; Beumer JH; Hurria A; Mortimer J; Piekarz R; Sand S; Herzog J; Van Tongeren LR; Ferry-Galow KV; Chen AP; Ruel C; Newman EM; Gandara DR; Weitzel JN
Clin Cancer Res; 2017 Aug; 23(15):4066-4076. PubMed ID: 28356425
[No Abstract] [Full Text] [Related]
7. A rare case of extremely high counts of circulating tumor cells detected in a patient with an oral squamous cell carcinoma.
Wu X; Mastronicola R; Tu Q; Faure GC; De Carvalho Bittencourt M; Dolivet G
BMC Cancer; 2016 Jul; 16():552. PubMed ID: 27465596
[TBL] [Abstract] [Full Text] [Related]
8. The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo.
Shrivastav A; Bruce M; Jaksic D; Bader T; Seekallu S; Penner C; Nugent Z; Watson P; Murphy L
Breast Cancer Res; 2014 May; 16(3):R49. PubMed ID: 24887419
[TBL] [Abstract] [Full Text] [Related]
9. [DNA ploidy is an independent prognostic biomarker in breast invasive ductal carcinoma].
Pinto AE; Pereira T; Silva GL; Ferreira MC; André S
Acta Med Port; 2012; 25(6):399-407. PubMed ID: 23534591
[TBL] [Abstract] [Full Text] [Related]
10. clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment.
Kim HJ; Im SA; Keam B; Kim YJ; Han SW; Kim TM; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Noh DY; Heo DS; Park IA; Bang YJ; Ha SW
J Neurooncol; 2012 Jan; 106(2):303-13. PubMed ID: 21938531
[TBL] [Abstract] [Full Text] [Related]
11. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
Bergamaschi A; Christensen BL; Katzenellenbogen BS
Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
[TBL] [Abstract] [Full Text] [Related]
12. Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome.
Shi H; Bevier M; Johansson R; Grzybowska E; Chen B; Eyfjörd JE; Hamann U; Manjer J; Enquist K; Henriksson R; Carlson J; Brandt A; Lascorz J; Butkiewicz D; Pamula-Pilat J; Tecza K; Herms S; Hoffmann P; Hemminki K; Lenner P; Försti A
Breast Cancer Res Treat; 2011 Dec; 130(3):905-16. PubMed ID: 21630024
[TBL] [Abstract] [Full Text] [Related]
13. Ethanol-induced in vitro invasion of breast cancer cells: the contribution of MMP-2 by fibroblasts.
Aye MM; Ma C; Lin H; Bower KA; Wiggins RC; Luo J
Int J Cancer; 2004 Dec; 112(5):738-46. PubMed ID: 15386367
[TBL] [Abstract] [Full Text] [Related]
14. Signal transducer and activator of transcription-5 activation and breast cancer prognosis.
Nevalainen MT; Xie J; Torhorst J; Bubendorf L; Haas P; Kononen J; Sauter G; Rui H
J Clin Oncol; 2004 Jun; 22(11):2053-60. PubMed ID: 15169792
[TBL] [Abstract] [Full Text] [Related]
15. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract] [Full Text] [Related]
16. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer.
Heimann R; Ferguson D; Powers C; Recant WM; Weichselbaum RR; Hellman S
J Natl Cancer Inst; 1996 Dec; 88(23):1764-9. PubMed ID: 8944007
[TBL] [Abstract] [Full Text] [Related]
